{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:06:47Z","timestamp":1789110407647,"version":"build-2803163510"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218778","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:25:59Z","timestamp":1786663559000},"page":"218778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter to the Editor: Comment on \u201cImmunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer\u201d"],"prefix":"10.1016","volume":"659","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8372-4976","authenticated-orcid":false,"given":"Ziwei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218778_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218702","article-title":"Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer","volume":"657","author":"Wu","year":"2026","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.canlet.2026.218778_bib2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.canlet.2026.218778_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7870","key":"10.1016\/j.canlet.2026.218778_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2026.218778_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.canlet.2026.218778_bib6","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:32:21Z","timestamp":1789108341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":6,"alternative-id":["S0304383526005422"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218778","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the Editor: Comment on \u201cImmunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer\u201d","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218778"}}